13-Jan-2026
Zymeworks announce key mangement changes
Seeking Alpha News (Mon, 12-Jan 7:32 AM ET)
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth
TipRanks (Mon, 12-Jan 6:34 AM ET)
Globe Newswire (Mon, 12-Jan 6:00 AM ET)
Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028
Seeking Alpha News (Sun, 11-Jan 11:43 PM ET)
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
TipRanks (Sun, 11-Jan 6:32 PM ET)
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Globe Newswire (Sun, 11-Jan 6:00 PM ET)
TipRanks (Fri, 9-Jan 7:30 AM ET)
Globe Newswire (Tue, 6-Jan 1:34 PM ET)
Zymeworks Announces Participation in Upcoming Conferences
Globe Newswire (Tue, 2-Dec 4:05 PM ET)
Globe Newswire (Tue, 18-Nov 8:45 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of January 13, 2026, ZYME stock price climbed to $23.92 with 900,181 million shares trading.
ZYME has a beta of 0.90, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.08 to the broad based SPY ETF.
ZYME has a market cap of $1.80 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $28 million in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.05.
In the last 3 years, ZYME traded as high as $28.49 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a return of +71.3%, while the SPY ETF gained +20.6%. In the last 3 month period, ZYME beat the market returning +32.1%, while SPY returned +4.9%. However, in the most recent 2 weeks ZYME has underperformed the stock market by returning -9.9%, while SPY returned +1.0%.
ZYME support price is $22.47 and resistance is $23.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.